ATE466840T1 - Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium - Google Patents

Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium

Info

Publication number
ATE466840T1
ATE466840T1 AT06809231T AT06809231T ATE466840T1 AT E466840 T1 ATE466840 T1 AT E466840T1 AT 06809231 T AT06809231 T AT 06809231T AT 06809231 T AT06809231 T AT 06809231T AT E466840 T1 ATE466840 T1 AT E466840T1
Authority
AT
Austria
Prior art keywords
carbonylü
fluorphenyl
phenylamino
methylethyl
pyrrole
Prior art date
Application number
AT06809231T
Other languages
English (en)
Inventor
Jason Leonard
Jonathan Miller
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE466840(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE466840T1 publication Critical patent/ATE466840T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT06809231T 2005-11-21 2006-11-09 Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium ATE466840T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73844705P 2005-11-21 2005-11-21
PCT/IB2006/003239 WO2007057755A1 (en) 2005-11-21 2006-11-09 Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium

Publications (1)

Publication Number Publication Date
ATE466840T1 true ATE466840T1 (de) 2010-05-15

Family

ID=37836758

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809231T ATE466840T1 (de) 2005-11-21 2006-11-09 Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium

Country Status (10)

Country Link
US (3) US8084488B2 (de)
JP (1) JP2007137885A (de)
AR (1) AR058212A1 (de)
AT (1) ATE466840T1 (de)
DE (1) DE602006014193D1 (de)
DK (1) DK1957452T3 (de)
ES (1) ES2304335T3 (de)
PT (1) PT1957452E (de)
TW (1) TW200738624A (de)
WO (1) WO2007057755A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1879862E (pt) * 2005-05-03 2011-04-19 Ranbaxy Lab Ltd Sais de magnésio de inibidores de hmg-coa-redutase
EP1963263A4 (de) * 2005-11-29 2009-09-02 Biocon Ltd Polymorphe von [r-(r*,r*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-magnesiumsalz (2:1)
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
KR20090128423A (ko) * 2007-04-13 2009-12-15 니콕스 에스. 에이. 아토르바스타틴 4-(니트록시)부틸 에스테르의 결정형
WO2009063476A1 (en) * 2007-11-16 2009-05-22 Biocon Limited A crystalline form of atorvastatin hemi magnesium salt and a process thereof
EP2130819A3 (de) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Kristalline Formen von Atorvastatin-Magnesium
WO2009157005A1 (en) * 2008-06-26 2009-12-30 Biocon Limited Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
KR100389518B1 (ko) 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
AU3515497A (en) * 1996-07-29 1998-02-20 Warner-Lambert Company Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
ES2284219T3 (es) * 1997-12-19 2007-11-01 Pfizer Ireland Pharmaceuticals Procedimiento de sintesis de 1,3-dioles.
US5959156A (en) * 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (de) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
EP2206497A1 (de) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphe Formen von Atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
EP1332130A4 (de) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatin hemi-kalzium form vii
CA2427255A1 (en) 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (de) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
SK16002003A3 (sk) * 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
US7361772B2 (en) * 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
BR0307720A (pt) 2002-02-14 2005-01-25 Ranbaxi Lab Ltd Formulações de atorvastatina estabilizadas com adições de metal alcalino, método para produzir uma formulação farmacêutica e estabilizar dita formulação
CN100406436C (zh) 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
AU2002330735A1 (en) 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1814541A4 (de) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd Stabile atorvastatin-formulierungen
US20080305158A1 (en) 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
EP1853249A2 (de) 2005-02-10 2007-11-14 LifeCycle Pharma A/S Stabile pharmazeutische zusammensetzung aus einer fixdosen-kombination von fenofibrat und einem hmg-coa-reductase-hemmer
PT1879862E (pt) 2005-05-03 2011-04-19 Ranbaxy Lab Ltd Sais de magnésio de inibidores de hmg-coa-redutase
EP2016048A4 (de) 2006-05-11 2010-06-23 Biocon Ltd Kristalline form b4 von atorvastatin-magnesium und verfahren dafür

Also Published As

Publication number Publication date
WO2007057755A1 (en) 2007-05-24
US8084488B2 (en) 2011-12-27
JP2007137885A (ja) 2007-06-07
US8383667B2 (en) 2013-02-26
TW200738624A (en) 2007-10-16
ES2304335T3 (es) 2010-05-19
DE602006014193D1 (de) 2010-06-17
US20100069459A1 (en) 2010-03-18
PT1957452E (pt) 2010-05-25
US20120059040A1 (en) 2012-03-08
AR058212A1 (es) 2008-01-23
US20130131138A1 (en) 2013-05-23
ES2304335T1 (es) 2008-10-16
US8648109B2 (en) 2014-02-11
DK1957452T3 (da) 2010-07-26

Similar Documents

Publication Publication Date Title
DE502007000290D1 (de) Neue Verwendungen von Nonenolid
PL1883439T3 (pl) Nebulizer
DE602006019282D1 (de) Schwingungsdämpfende zusammensetzung
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
ATE549333T1 (de) Neue sulfonylpyrrole als hdac-inhibitoren
EP1796359A4 (de) Sip-server
EP1902539A4 (de) Erweiterung von benutzerabbildungsinformationen für protokolle
EP1852679A4 (de) Oszillierender kreiselsensor
DE602006004463D1 (de) Kristallform von asenapinmaleat
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DE602006008458D1 (de) Formen von kontaktlinsen
ATE538101T1 (de) Neue verbindungen iii
EP1840750A4 (de) Av-server
DE502007000436D1 (de) Neue Verwendungen von 4-Methyl-5-hydroxy-hexansäurelacton
DE602006000877D1 (de) Emulsionszusammensetzung
ATE466840T1 (de) Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1971695A4 (de) Gewinnung von festem magnesiumsulfathydrat
DE602005023145D1 (de) Neue androgene
DE602006012594D1 (de) Emulsion zur Beschichtung von Aussenwänden
EP1937255A4 (de) Pharmazeutische zusammensetzung
DE602005003557D1 (de) Amorphe formen von of risedronat-mononatrium
DE502006006886D1 (de) Hydropneumatisch gefederte Radaufhängung
EP1862184A4 (de) Pharmazeutische zusammensetzung
FI20055587L (fi) Sihtisylinteri
DE602006014898D1 (de) Farbdruck

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1957452

Country of ref document: EP